4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors
申请人:Novartis AG
公开号:US08193349B2
公开(公告)日:2012-06-05
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives
申请人:Mogi Muneto
公开号:US08420641B2
公开(公告)日:2013-04-16
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
申请人:Novartis AG
公开号:EP2463282A1
公开(公告)日:2012-06-13
The present invention provides a compound of formula (I):
wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP (cholesteryl ester transfer protein), and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.